MagnoshininCAS# 86702-02-5 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 86702-02-5 | SDF | Download SDF |
| PubChem ID | 442896 | Appearance | Powder |
| Formula | C24H30O6 | M.Wt | 414.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (1S,2R)-5,7,8-trimethoxy-2,3-dimethyl-1-(2,4,5-trimethoxyphenyl)-1,2-dihydronaphthalene | ||
| SMILES | CC1C(C2=C(C=C1C)C(=CC(=C2OC)OC)OC)C3=CC(=C(C=C3OC)OC)OC | ||
| Standard InChIKey | MWJAXRZVJODRGN-FPTDNZKUSA-N | ||
| Standard InChI | InChI=1S/C24H30O6/c1-13-9-15-18(26-4)12-21(29-7)24(30-8)23(15)22(14(13)2)16-10-19(27-5)20(28-6)11-17(16)25-3/h9-12,14,22H,1-8H3/t14-,22-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Magnoshinin Dilution Calculator
Magnoshinin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4125 mL | 12.0627 mL | 24.1255 mL | 48.2509 mL | 60.3136 mL |
| 5 mM | 0.4825 mL | 2.4125 mL | 4.8251 mL | 9.6502 mL | 12.0627 mL |
| 10 mM | 0.2413 mL | 1.2063 mL | 2.4125 mL | 4.8251 mL | 6.0314 mL |
| 50 mM | 0.0483 mL | 0.2413 mL | 0.4825 mL | 0.965 mL | 1.2063 mL |
| 100 mM | 0.0241 mL | 0.1206 mL | 0.2413 mL | 0.4825 mL | 0.6031 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- ROCK inhibitor
Catalog No.:BCC1905
CAS No.:867017-68-3
- (S)-Methylisothiourea sulfate
Catalog No.:BCC6791
CAS No.:867-44-7
- (R)-(+)-2-Amino-3-methyl-1,1-diphenyl-1-butanol
Catalog No.:BCC8394
CAS No.:86695-06-9
- ARL 17477 dihydrochloride
Catalog No.:BCC7647
CAS No.:866914-87-6
- BINA
Catalog No.:BCC7849
CAS No.:866823-73-6
- (1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutane hydrochloride
Catalog No.:BCC8383
CAS No.:866783-13-3
- Yuexiandajisu E
Catalog No.:BCN3775
CAS No.:866556-16-3
- Yuexiandajisu D
Catalog No.:BCN3774
CAS No.:866556-15-2
- [Ala2,8,9,11,19,22,24,25,27,28]-VIP
Catalog No.:BCC5973
CAS No.:866552-34-3
- 7-Hydroxy-3-prenylcoumarin
Catalog No.:BCN4415
CAS No.:86654-26-4
- Dorsomorphin
Catalog No.:BCC5131
CAS No.:866405-64-3
- DPPI 1c hydrochloride
Catalog No.:BCC2363
CAS No.:866396-34-1
- Tropanyl 3-hydroxy-4-methoxycinnamate
Catalog No.:BCN1325
CAS No.:86702-58-1
- Colivelin
Catalog No.:BCC7821
CAS No.:867021-83-8
- Linsitinib
Catalog No.:BCC3697
CAS No.:867160-71-2
- TRC 051384
Catalog No.:BCC7968
CAS No.:867164-40-7
- TG 100572 Hydrochloride
Catalog No.:BCC1995
CAS No.:867331-64-4
- TG 100801
Catalog No.:BCC1996
CAS No.:867331-82-6
- TG 100572
Catalog No.:BCC1994
CAS No.:867334-05-2
- Astrasieversianin VII
Catalog No.:BCN2788
CAS No.:86764-11-6
- CRF (human, rat)
Catalog No.:BCC5710
CAS No.:86784-80-7
- H-Cys-OEt.HCl
Catalog No.:BCC2904
CAS No.:868-59-7
- Carasiphenol C
Catalog No.:BCN8251
CAS No.:868168-04-1
- SID 7969543
Catalog No.:BCC6026
CAS No.:868224-64-0
Inhibitory effects of anti-rheumatic drugs containing magnosalin, a compound from 'Shin-i' (Flos magnoliae), on the proliferation of synovial cells in rheumatoid arthritis models.[Pubmed:9716260]
Immunopharmacology. 1998 May;39(2):139-47.
This study was undertaken to examine the effects of magnosalin, a compound isolated from 'Shin-i' (Flos magnoliae) on proliferation of synovial cells isolated from MRL/1pr and collagen-induced arthritis (CIA) mice, and rheumatoid arthritis (RA) patients. Magnosalin (2.39-23.9 microM) inhibited 5% fetal bovine serum (FBS)-stimulated [3H]-thymidine incorporation into the synovial cells in the MRL/1pr mice. The effect of magnosalin was greater than that of hydrocortisone, bucillamine and Magnoshinin (another compound from 'Shin-i'), but weaker than that of corticosterone. The effects of magnosalin for FBS-induced thymidine incorporation into the cells of the CIA mice and the RA patients were significantly greater than those in the corresponding control mice and osteoarthritis patients. Interleukin (IL)-1alpha increased the incorporation of thymidine into the synovial cells in the C57BL/6J mice to a greater degree than did basic fibroblast growth factor (bFGF) or platelet-derived growth factor BB-homodimer (PDGF-BB). The inhibitory effect of magnosalin on the submaximal action of IL-1alpha was significantly greater than that of bFGF, PDGF-BB or FBS. These results offer evidence that magnosalin suppresses the proliferation of synovial cells in RA models by inhibiting IL-1alpha-stimulated action.
Inhibitory effect of magnosalin derived from Flos magnoliae on tube formation of rat vascular endothelial cells during the angiogenic process.[Pubmed:8913501]
Biol Pharm Bull. 1996 Oct;19(10):1304-6.
An aqueous water extract of Flos magnoliae, a Japanese Sino-medicine, inhibits angiogenesis in adjuvant-induced mouse pouch granuloma. Magnosalin (MSA) and Magnoshinin (MSI), neolignans isolated from magnolia, have a crucial role in the anti-angiogenic effect of magnolia (Kimura et al., Int. Arch. Allergy Appl. Immunol., 93, 365 (1990); Phytother. Res., 6, 209 (1992)). We investigated the effects of these neolignans on tube formation of endothelial cells (EC) cultured in type I collagen gel during the angiogenic process. MSA (0.1-10 microM), MSI (0.23-7 microM) and corticosterone (CS: 0.3-30 microM) inhibited fetal bovine serum (FBS)-stimulated tube formation in a concentration-dependent manner. Their 30% inhibitory concentration (IC30, 95% confidence limits) values were 0.51 (0.20-1.27) for MSA, 8.14 (2.48-26.7) for MSI and 3.65 microM (2.47-5.40) for CS, respectively. MSA and MSI (1-3 microM) also inhibited interleukin (IL)-1 alpha-stimulated tube formation in a concentration-dependent manner. Their IC50 values (95% confidence limits) were 1.22 (1.01-1.47) for MSA and 0.74 microM (0.24-2.31) for MSI against a submaximal concentration (69 pM) of IL-1 alpha-stimulated tube formation. Their inhibitory effects on the action of IL-1 alpha were non-competitive. These results demonstrate that MSA inhibited FBS-stimulated tube formation with a greater potency than MSI. The inhibitory effect of MSA on the action of FBS differed from that on the action of IL-1 alpha.
Inhibitory effects of magnoshinin and magnosalin, compounds from "Shin-i" (Flos magnoliae), on the competence and progression phases in proliferation of subcultured rat aortic endothelial cells.[Pubmed:1460807]
Jpn J Pharmacol. 1992 Sep;60(1):59-62.
Anti-proliferative effects of Magnoshinin and magnosalin derived from "Shin-i" (Flos magnoliae) were investigated using subcultured endothelial cells (EC) of rat aorta. The inhibitory effects of Magnoshinin were 2-fold greater at 10 micrograms/ml than that of magnosalin on the increase in cell number when EC were stimulated by 5% fetal bovine serum. In the 3H-thymidine incorporation monitored at 3 hr-intervals, Magnoshinin (0.1-3 micrograms/ml) prolonged the starting time of DNA synthesis and reduced the rate of incorporation into EC. Magnosalin (0.3-3 micrograms/ml) reduced only the incorporation rate. These results suggest that Magnoshinin inhibits both the competence phase and progression phase, but magnosalin preferentially inhibits the progression phase in EC proliferation.
Selective inhibition by magnosalin and magnoshinin, compounds from "Shin-i" (Flos magnoliae), of adjuvant-induced angiogenesis and granuloma formation in the mouse pouch.[Pubmed:1712537]
Agents Actions Suppl. 1991;32:197-201.
Inhibitory effects of magnosalin and Magnoshinin, compounds from the crude drug "Shin-i" (Flos magnoliae), on angiogenesis and pouch granuloma formation in mice induced by an adjuvant containing croton oil were investigated. The anti-chronic inflammatory effect of "shin-i" was caused by selective inhibition of angiogenesis by magnosalin and of granuloma formation by Magnoshinin.
Selective inhibition by magnosalin and magnoshinin, compounds from 'shin-i' (Flos magnoliae), of adjuvant-induced angiogenesis and granuloma formation in the mouse pouch.[Pubmed:1713572]
Int Arch Allergy Appl Immunol. 1990;93(4):365-70.
Inhibitory effects of magnosalin and Magnoshinin, compounds from the crude drug 'Shin-i' (Flos magnoliae), on angiogenesis and pouch granuloma formation induced by an adjuvant containing croton oil were investigated. Magnosalin inhibited angiogenesis 2.4-fold (intra-pouch) and 9.7-fold (intraperitoneal) more strongly than granuloma formation. The inhibition of angiogenesis by magnosalin was 5-fold (intra-pouch) and 21-fold (intraperitoneal) weaker than that by hydrocortisone. In contrast, intraperitoneal Magnoshinin inhibited granuloma formation 2.5-fold more strongly than angiogenesis. The regression coefficients of anti-angiogenesis vs. the inhibition of granuloma formation were 1.79 for magnosalin, 1.11 for hydrocortisone, and 0.61 for Magnoshinin. These results show that the anti-chronic inflammatory effect of 'Shin-i' was caused by selective inhibition of angiogenesis by magnosalin and of granuloma formation by Magnoshinin.
Anti-Inflammatory Effect of Neolignans Newly Isolated from the Crude Drug "Shin-i" (Flos Magnoliae).[Pubmed:17340515]
Planta Med. 1985 Aug;51(4):291-3.
The anti-inflammatory effects of the major components of the dried flower buds of MAGNOLIA SALICIFOLIA were determined using the pouch granuloma method in mice. Though alkaloids, fatty acids, essential oils, and lignans had no anti-inflammatory effects, neolignans (Magnoshinin and magnosalin) significantly inhibited the granuloma tissue formation. The inhibitory effect of Magnoshinin was particularly strong, being nearly half of that of hydrocortisone acetate when administered orally. Some differences were noted in the mode of action between the neolignans and the steroidal drugs as the neolignans selectively inhibited the granuloma tissue formation but did not affect the exudation of pouch fluid. The structural specificity of neolignans was also found on their anti-inflammatory effect.
